Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 42
Summary
- Conditions
- Multiple Myeloma
- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Chronic Myelomonocytic Leukemia
- High Risk Myelodysplastic Syndrome
- Relapsed or Refractory Haematological Malignancies Including
- Richter's Syndrome
- Small Lymphocytic Lymphoma
- T Cell Non-Hodgkin Lymphoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This study is a multicentre, open-label, first in human, non-randomized, dose-escalation study including an intra-subject ramp-up. The study will consist of two, parallel dose escalation armsMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 130 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03263637
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon